KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Equity Income: 2024

Historic Equity Income for Castle Biosciences (CSTL) over the last 1 years, with Dec 2024 value amounting to $600,000.

  • Castle Biosciences' Equity Income was N/A to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $600,000 for FY2024, which is N/A change from last year.
  • Castle Biosciences' Equity Income amounted to $600,000 in FY2024.
  • In the past 5 years, Castle Biosciences' Equity Income registered a high of $600,000 during FY2024, and its lowest value of $600,000 during FY2024.
  • Over the past 1 years, Castle Biosciences' median Equity Income value was $600,000 (recorded in 2024), while the average stood at $600,000.